[Federal Register Volume 71, Number 178 (Thursday, September 14, 2006)]
[Notices]
[Page 54297]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-15216]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Use of a Complete T-Cell 
Receptor Recognizing MART-1 Peptide Restricted by HLA-A2, Incorporated 
in a Continuous T-Lymphocyte Cell Line Developed or Owned by Licensee 
To Treat Cancer

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
part 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive patent license to practice the inventions embodied in U.S. 
patent 5,830,755 filed March 27, 1995 [HHS Ref. No. E-093-1995/0-US-01] 
and Australian Patent 709122 filed March 27, 1996 [HHS Ref. No. E-093-
1995/0-AU-03], entitled T-Cell Receptors and Their Use in Therapeutic 
and Diagnostic Methods, to CellCure A/S, which is located in Aarhus, 
Denmark. The patent rights in these inventions have been assigned to 
the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to the use of a complete T-cell 
receptor MART-1 peptide restricted by HLA-A2 incorporated into a 
continuous T-Lymphocyte cell line developed or owned by licensee to 
treat cancer.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
November 13, 2006 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Michelle A. Booden, Ph.D., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; telephone: (301) 451-7337; facsimile: (301) 402-0220; e-
mail: [email protected].

SUPPLEMENTARY INFORMATION: The technology describes the composition and 
use of nucleic acid sequences that encode polypeptides capable of 
forming a T-cell receptor (TCR) in a genetically engineered cell. 
Specifically, these nucleic acid sequences will encode TCR's specific 
to tumor associated antigens (TAA), MART-1. T-Cells engineered with 
these tumor associated antigen specific TCRs show specific immune 
responses against TAA expressing cancer cells. Additionally, a method 
of treating or preventing cancer by administrating the above described 
TCRs is also disclosed.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404.7. The prospective exclusive license may be granted unless within 
sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR part 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Date: September 7, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E6-15216 Filed 9-13-06; 8:45 am]
BILLING CODE 4167-01-P